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Alzheimer’s disease (AD) is the most prevalent age-related dementia affecting millions of people worldwide. Its main pathological
hallmark feature is the formation of insoluble protein deposits of amyloid-𝛽 and hyperphosphorylated tau protein into extracellular
plaques and intracellular neurofibrillary tangles, respectively. Many of the mechanistic details of this process remain unknown, but
a well-established consequence of protein aggregation is synapse dysfunction and neuronal loss in the AD brain. Different pathways
including mitochondrial dysfunction, oxidative stress, inflammation, and metal metabolism have been suggested to be implicated
in this process. In particular, a body of evidence suggests that neuronal metal ions such as copper, zinc, and iron play important
roles in brain function in health and disease states and altered homeostasis and distribution as a common feature across different
neurodegenerative diseases and aging. In this focused review, we overview neuronal proteins that are involved in AD and whose
metal binding properties may underlie important biochemical and regulatory processes occurring in the brain during the AD
pathophysiological process.
1. Alzheimer’s Disease: Hallmark Amyloid
Aggregation and Neuronal Dysfunction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized by cognitive decline.Theneuropathol-
ogy hallmarks are gross atrophy of the cortex and hippocam-
pus, and the accumulation of amyloid-beta (A𝛽) into senile
plaques and of hyperphosphorylated tau into neurofibrillary
tangles. The deposition of A𝛽 and hyperphosphorylated tau
aggregates in the human brain occurs in opposite directions
with an orderly neuroanatomical pattern. Amyloid plaques
first appear in the neocortex and slowly progress through the
striatum, the basal cholinergic nuclei, the brain stem, and
finally the cerebellum [1]. The deposition of tangles begins
in the brain stem and progresses towards the neocortex [2].
Thus, the common presence of amyloid plaques and tau
neurofibrillary tangles in the cortex only happens at late
stages of the disease.
AD is heterogeneous andmultifactorial with sporadic and
familial forms [3–6]. The large majority of patients have the
sporadic form or late onset dementia (later than 65 years).
The few remaining patients have the familial form with early
onset dementia (around 30 years to 65 years) andmay present
different symptoms. These patients have mutations in one of
three genes encoding proteins essential for A𝛽 formation:
the amyloid precursor protein (APP) and presenilins 1 and
2 (PSEN1/2) [7–10]. Presenilins are components of catalytic
subunit of 𝛾-secretase multicomplex, responsible for the
cleavage of APP and formation of A𝛽. The origin of the
sporadic form is complex involving multiple genetic and
environmental risk factors, for example, the presence of
apolipoprotein E-𝜀4 allele, mitochondrial dysfunction, head
injury, or a compromised brain blood barrier [3, 11]. Despite
the fact that AD is the most common form of dementia of
the elderly and affects millions of people worldwide, the exact
cause of this disorder is still unknown. The genetic evidence
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obtained from the rare familial form of AD supports the
hypothesis that the accumulation of A𝛽 plaques is at the
origin of the disease. This is the foundation for the amyloid-
𝛽 cascade hypothesis [12] which has been the central theory
in AD research for the last three decades. According to this
hypothesis, the deposition of A𝛽 is the initial event and it is
sufficient to trigger the cascade of pathological and clinical
changes in AD, which are the formation of senile plaques
and neurofibrillary tangles and subsequent neuronal death,
vascular damage, and dementia [12]. Although senile plaque
deposition is an early event in the disease, as observed in
postmortem human brains [1], plaque accumulation in the
brain does not correlate with dementia [13] implying that
other mechanisms are associated with neurodegeneration.
Notably, therapies designed until now that aimed at targeting
amyloid plaques and APP proved to be largely unsuccessful.
An increasing amount of data challenges the amyloid-𝛽
cascade hypothesis.
Therefore, efforts to integrate the other pathogenic fea-
tures of AD and multiple etiology pathways into a more
global model are now needed. During the course of AD, tau
is hyperphosphorylated and accumulates in the somatoden-
dritic compartment as paired helical filaments and straight
filaments [14]. In neurons, tau is the major microtubule
associated protein and stabilizes its structure. Tau interacts
with tubulin promoting its assembly into microtubules. The
level of phosphorylation regulates the activity of tau and
hyperphosphorylation suppresses its microtubule assembly
activity. In addition, hyperphosphorylated tau sequesters
normal tau and other microtubule associated proteins that
further contribute to microtubule disassembly [15]. There-
fore, the abnormal phosphorylation of tau results in loss of
normal function and gain of toxic function in the AD brain.
The formation of neurofibrillary tangles does correlate with
cognitive decline and with neuronal and synapse loss [13, 16].
Senile plaques are extracellular deposits composed
mainly of amyloid peptides ranging from 39 to 43 amino
acids, which are natural metabolites of APP generated by
sequential cleavage by 𝛽-secretase and 𝛾-secretase l [17]. The
APP is a transmembrane protein necessary for neurogen-
esis, for neurite outgrowth and guidance, and for synapse
formation and repair [18]. APP is processed in different
ways through different enzymes leading to the formation
of amyloidogenic and nonamyloidogenic precursors. The
processing of APP results in the formation of soluble 𝛼-
and 𝛽-secreted APP (sAPP) which is cleaved by 𝛼- and 𝛽-
secretase, respectively. As a product in the nonamyloidogenic
pathway, sAPP𝛼 promotes neuronal survival and neurite
outgrowth, among other beneficial neuronal functions. Con-
trarily, sAPP𝛽 is not involved in the beneficial functions
of sAPP𝛼, participating in synapse pruning. A𝛽 is secreted
through sequential APP cleavage by 𝛽- and 𝛾-secretases,
resulting in peptides that can range from 39 to 43 amino
acids. The A𝛽 peptides are catabolized by multiple amyloid
degrading enzymes, for example, neprilysin and insulin-
degrading enzyme [19]. It is the imbalance between the
production and clearance of A𝛽 that triggers its deposition
as amyloid plaques. However, several studies suggest that
A𝛽 has a physiological role in the synapses and its complete
removal induces neuronal cell death [20–22]. In addition to
the aggregates, A𝛽 is also present in soluble oligomeric forms
in APP-transgenic mice and human diseased brains [20].
Compared to A𝛽 aggregates, the soluble oligomers are highly
neurotoxic [23]. Therefore, it is possible that aggregation
of A𝛽 into plaques is a neuroprotective mechanism that
eliminates the toxic oligomeric forms [15].
Thenormal functions of synapses are impaired during the
course of AD. Synapse loss correlates with dementia suggest-
ing that it is important for disease progression and for the
degeneration process [24]. Dense plaque deposition causes
the surrounding neurites to bend and change trajectory,
which can lead to changes in synapse signal transmission.
Also, gliosis and oxidative stress are observed in the vicinity of
plaques. During normal development of the brain, microglia
are involved in synaptic pruning after birth and it is possible
that in the diseased AD brain the recruitment of activated
microglia around the plaques participates in the synapse
loss [24]. In addition to aggregates, the oligomeric forms
of A𝛽 obtained from cultured cells or from human AD
brain disturb synapses and lead to cognition impairment
in injected mice [25–27]. Comparably, evidence also shows
that soluble forms of tau are toxic for synapses [28]. The
molecular mechanisms that lead to synapse dysfunction and
neuronal loss downstream of A𝛽 and tau are not completely
identified but different pathways are implicated such as
mitochondrial dysfunction, oxidative stress, inflammation,
and dysregulation of metal homeostasis.
2. Metals and Metal Binding Proteins
Implicated in AD
Metal ions play essential roles in the brain and there is
solid evidence pointing to their homeostatic dysfunction
across different neurodegenerative diseases (e.g., [29–31]).
This includes the first row transition metals, iron, copper,
and zinc and also calcium, whose homeostasis is important
for neuronal function and during aging [32–34]. One major
hypothesis for this cross talk, which has been put forward
since a number of years and which has been elegantly
reviewed in [35], proposes that AD is as much as ametallopa-
thy as a proteinopathy. Indeed, age-relatedmetal ion dysfunc-
tion altered levels of neuronalmetal ions in AD-affected areas
including accumulation in protein deposits, and the interplay
between metal ions and AD pathological proteins indicates
a close relationship between protein misfolding, aggregation,
andmetal ion homeostasis. In AD patients, it has been shown
that Cu2+, Zn2+, and Fe2+ are found in the core and rims
of senile plaques [36, 37] and colocalize with A𝛽 [38]. This
has led to the suggestion that metal ion sequestration into
plaques could lead to deficient distribution of these metals
in the neighbouring regions [39]. Moreover, it is described
that in AD patients Zn2+ is decreased in serum and blood
but increased in the cerebrospinal fluid and neocortical tissue
[40–42]. In addition, Zn2+, Cu2+, and Fe2+ are increased in
the neuropil of AD patients [36, 43]. In agreement with a
role of metal ions in pathology, molecules designed to chelate
Zn2+ and Cu2+ from amyloid-beta aggregates [44, 45] were
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Figure 1: Modulation of amyloid-𝛽 aggregation by Cu2+ and Zn2+ binding. A𝛽 aggregation into fibrils is a complex pathway that involves
multiple intermediate precursor species. The scheme is a simplification depicting direct effects of Cu2+ and Zn2+ on A𝛽 aggregation.
Superstoichiometric levels of Cu2+ and Zn2+ (Zn2+/Cu2+: A𝛽 ≫ 1) result in insoluble and amorphous aggregates rather than organized
fibrils, while equimolar Cu2+ and Zn2+ (Zn2+/Cu2+: A𝛽 ≈ 1) induce amorphous aggregates, which slowly convert to fibrils. At subequimolar
Cu2+ levels (Cu2+: A𝛽 < 1), the kinetics of fibril formation are accelerated.TheAD amyloid plaques, depicted in a representation at the bottom
right corner of the figure, contain high levels of Zn (1055𝜇M), Fe (940𝜇M), and Cu (390 𝜇M), as reviewed in [35]. See text for details.
found to decrease A𝛽 deposits in mice models due to A𝛽
solubilisation [45]. Here, as a contribution for a broader
molecular and biochemical analysis of protein-metal cross
talks in neurodegeneration, we undertake an overview of
proteins with metal binding properties which are implicated
in AD (Table 1).
2.1. Amyloid-𝛽. Metal ions have been acknowledged as
important players of the pathological effects of A𝛽 aggrega-
tion in AD and have been considered as possible modulators
of A𝛽 misfolding and aggregation due to their binding to
the A𝛽 peptide [46–49] and to amyloid fibrils [50, 51].
Cu2+, Zn2+, and Fe2+ bind to A𝛽 influencing its aggregation
pathway and are found in and nearby extracellular senile
plaques [29, 36]. The binding of metal ions to A𝛽 invariably
results in aggregationwhichmay either be into amyloid fibers
or into amorphous aggregates, depending on the metal ion,
stoichiometry, and environmental conditions [49]. In spite of
contradictory findings, there seems to be a consensus that
(a) superstoichiometric levels of Cu2+ and Zn2+ result in
insoluble and amorphous aggregates rather than organized
fibrils [49, 52–55]; (b) equimolar Zn2+ and Cu2+ induce
amorphous aggregates, which slowly convert to fibrils [56,
57]; and (c) at subequimolar Cu2+ levels, the kinetics of
fibril formation are accelerated [52, 58, 59] (Figure 1). The
observation that high levels of Zn2+ and Cu2+ seem to shift
aggregation into oligomeric precursors rather than organized
fibrils has important consequences in brain function, as these
A𝛽 precursors are now known to be the neurotoxic self-
propagating species causing neurodegeneration. Further-
more, Cu2+ and Fe2+ participate in ROS production causing
oxidative stress and neuronal damage, thus being one of
the causes that potentiate A𝛽 toxicity [60–62]. Indeed, the
formation ofH
2
O
2
as a product of the interaction betweenA𝛽
and Cu2+ can generate hydroxyl radicals, which are related
to AD pathology [63]. Superoxide has also been recently
shown to be an intermediate of the reaction leading to the
production ofH
2
O
2
byCu+-A𝛽 andO
2
[64]. Zinc and copper
chelators inhibit A𝛽 plaque deposition in AD patients [44,
65, 66], further suggesting that amyloid pathology may arise
from the dysregulation of these metal ions. Excess of iron
increases A𝛽 production [67] and leads to the formation of
annular protofibrils [68] and slows down the formation of
ordered cross-𝛽 fibrils [69] towards the formation of shorter
and less ordered aggregates [53, 69] which are potentially
more toxic.
2.2. Tau. Tau is a disordered cytosolic protein involved in
microtubule assembly and stability whose aggregation and
toxic deposition are triggered by hyperphosphorylation.This
results in the formation of intracellular tau paired helical
filaments (PHF), which ultimately gather to form the charac-
teristic neurofibrillary tangles (NFT) [70, 71], a process which
is modulated by metal ions [30] (Figure 2). Zn2+ binds tau
and promotes its hyperphosphorylation [72]; however, low
concentrations of zinc induce fibril formation whereas high
concentrations induce granular aggregates [73]. Fe3+ also
binds to hyperphosphorylated tau and induces its aggregation
[74, 75], mostly into PHF [75]; however, reduction to Fe2+ can
reverse aggregation of tau [75]. Excess of iron is accumulated
in NTF [76, 77] generating oxidative stress due to the Fenton
reaction and perpetuating tau hyperphosphorylation [78].
The role of Cu2+ in tauopathies is controversial. Some studies
suggest that tau binds Cu2+ [79], inhibiting its aggregation
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Figure 2: Modulation of tau aggregation by metal ions. Hyperphosphorylated (P) tau undergoes aggregation, which is influenced by metal
ion binding. Tau phosphorylation facilitates Fe3+ binding that promotes the formation of paired helical filaments (PHF) and further tau
fibrillation. The reduction of Fe3+ to Fe2+ reverts PHF formation. Zn2+ binding at high ratios promotes the formation of amorphous tau
oligomers, whereas, at low ratios, PHF are formed. Both Ca2+ and Mg2+ binding to PHF favour the conversion into amorphous off-pathway
aggregates. A neurofibrillary tangle is depicted in a representation at the bottom left corner of the figure. See text for details. Adapted from
[30].
in vitro [80] while promoting tau hyperphosphorylation in
hippocampal neurons [81]. Other studies however suggest
that addition of copper-bis(thiosemicarbazone) complexes
that increase intracellular copper in AD mice brains inhibits
tau phosphorylation [82].
2.3. Amyloid-Beta Precursor Protein. Abnormal processing
of the amyloid precursor protein leads to neurotoxic A𝛽
production. The proteolytic processing of APP is influenced
by metal ions, by protein ligands, and by the APP oligomer-
ization state. Cu2+ and Zn2+ promoteAPP expression [83–85]
and possibly interfere with A𝛽 metabolism. Cu2+ enhances
APP dimerization and increases extracellular release of A𝛽
[86]; yet, other studies suggest that high copper concen-
trations modulate APP processing leading to reduced A𝛽
production [87]. Interestingly, APP contains a copper binding
domain and a site that favours Cu+ coordination, which
has led to the suggestion that it could act as a neuronal
metallotransporter [87]. Recent structural and biochemical
studies have uncovered a high-affinity binding site within
the E2 domain that binds competitively Cu2+ and Zn2+
at physiological concentrations [88]. Metal binding results
in large conformational changes and in different structural
states that regulate the function of APP and A𝛽 metabolism
[89]. Indeed, APP can be a mediator of Cu neurotoxicity
since it was shown that in primary neuronal cultures APP
loaded with Cu2+ induces cell death [90]. This may possibly
involve catalytic reduction of Cu2+ to Cu+ leading to an
increase in oxidative stress in neurons [91].The links between
APP and metal metabolism are further emphasized by the
interaction of APP with ferroportin, to promote iron export
and its ferroxidase activity [92, 93]. APP ferroxidase activity is
inhibited by Zn2+ binding contributing to Fe2+ accumulation
in AD brains [92].
2.4. Presenilin-1. Presenilin-1 (PS-1) is a component of the
𝛾-secretase multicomplex, responsible for the cleavage of
APP. Presenilins have an activity as low-conductance pas-
sive ER Ca2+ leak channels which is independent of 𝛾-
secretase activity [94]. Overexpression of presenilin results
in increased Ca2+ release whose levels are restored by 𝛾-
secretase inhibitors [95]. Mutations in presenilins as in
familial AD forms result in downregulation of Ca2+ chan-
nels and Ca2+-dependent mitochondrial transport proteins,
strengthening the relationship between Ca2+ homeostasis
and presenilin [94, 96, 97]. A recent study based on the effects
ofmetal chelators on 𝛾-secretase suggests that Ca2+ andMg2+
stabilize 𝛾-secretase and enhance its activity [98].
2.5. Metallothionein 3. Metallothioneins are a family of ubiq-
uitous proteinswithmetal binding properties and antioxidant
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activity [99]. Neuronal metallothionein 3 (MT3), which is
involved in the transport and homeostasis of Zn2+ and Cu2+,
plays an important role in several AD related pathways. MT3
is decreased in AD patients [100] and in Tg2576 mice [101],
which can lead to aberrant neuritic sprouting [100]. Addi-
tionally, MT3 increases sAPP𝛼 (soluble amyloid precursor
protein 𝛼) levels and reduces A𝛽 production [102], through
an increase in ADAM10 (a disintegrin and metallopeptidase
10). ADAM10 is a protein responsible for the cleavage of APP-
derived peptides and activation of the nonamyloidogenic
pathway [103]. Mechanistically, it has been reported that
the 𝛽-domain of MT3 interacts with A𝛽, abolishing Cu2+
mediated aggregation [104, 105] and ROS production [104].
It has also been suggested that rapid metal exchange between
Zn2+-MT3 and Cu2+-A𝛽 [106] or Zn2+ release by MT3 [107]
promotes structural changes in A𝛽 aggregates. In agreement
with this, in primary neuron cultures, MT3 inhibits the
formation of toxic A𝛽 aggregates alleviating their neurotoxic
effects [105, 108]. One possible mechanism for this effect may
be related to the observed metal swapping between MT3 and
soluble and aggregated A𝛽, which abolishes the production
of Cu-induced ROS [104, 109].
2.6. Zinc Transporter 3. Zinc transporter 3 (ZnT3) is a
synaptic Zn2+ transporter responsible for loading zinc into
presynaptic vesicles. This protein is highly expressed in
the brains of AD transgenic mice, in which it colocalizes
with amyloid plaques [110–112], where zinc is also found
at high concentrations. Zinc sequestering within amyloid
plaques has been suggested to provoke an imbalance in the
cellular environment with concurrent effects on overall metal
metabolism and protein homeostasis [35]. ZnT3 has been
shown to decrease with aging and AD, contributing to the
aggravation of zinc-mediated cognitive decline [113]. In the
AD Tg2576 transgenic mouse model with a ZnT3 knockout,
cerebral A𝛽 deposition was nearly abolished by the lack of
synaptic Zn2+ [58, 59]. ZnT3 and other zinc transporters,
such as ZnTs 1, 4, 5, 6, and 7, are also found upregulated in
amyloid plaques of human AD brains near Zn2+ enriched
terminals [60], revealing a cross talk between zinc induced
amyloid plaques and zinc transporters. In ZnT3 knockout
mice, the addition of metal chaperones results in restoration
of expression of the synaptic proteins PSD-95, AMPAR,
and NMDAR2b, due to the restitution of hippocampal zinc
content [113].
2.7. ProSAP/Shank Scaffold Proteins. ProSAPs/Shanks are
zinc-regulated multidomain proteins that are important
scaffolding molecules of the postsynaptic density (PSD), a
protein dense structure composed of both membranous and
cytoplasmic proteins localized at the postsynaptic plasma
membrane of excitatory synapses [114]. Deregulation of
ProSAP/Shank has been reported in AD: in patients brains
and in transgenic mice models, the accumulation of A𝛽
oligomers is accompanied by reduction of synaptic scaffold
protein levels, such as Shank1 and ProSAP2/Shank3 [115],
and disruption of the Homer1b and Shank1 scaffolds [116].
Interestingly, sequestration of Zn2+ by A𝛽 leads to less
mature synapses by decreasing Shank1 protein levels at the
postsynaptic density in hippocampal neurons [117]. Future
studies will further elucidate the mechanistic cross-links
between the presence of A𝛽, zinc levels, and the scaffolding
PSD proteins in the context of AD [118].
2.8. Ferritin. Ferritin is the major intracellular iron storage
protein in the body. It has elevated levels in AD brain
tissue [119–121] and is found in the vicinity of AD plaques
[120], suggesting that ferritin trapped within the plaque
inclusions may block the transport of iron between cells.
The loss of integrity of hippocampus tissue of AD patients
is linked with the increase of ferritin [122] and with a
reduction of ferroportin protein levels [123]. Effectively, the
impact of iron on AD outcomes is not fully explored but a
recent longitudinal study has shown that ferritin is strongly
associated with cerebrospinal fluid apolipoprotein E levels; in
turn, ferritin is elevated by the Alzheimer’s risk allele, APOE-
𝜀4 [124]. This study speculates that the APOE-𝜀4 genotype
raises the baseline iron load in the AD brain, lowering the
threshold for iron-mediated neuronal loss, a hypothesis that
remains to be experimentally addressed.
2.9. S100 Proteins. S100 proteins are a family of at least 21
different vertebrate-specific proteins with two Ca2+-binding
EF-hand type sites and in some cases additional sites for Zn2+
and Cu2+ [125]. S100 proteins are part of the inflammatory
response and a number of these proinflammatory cytokines
(S100B, S100A6, S100A7, S100A1, S100A9, and S100A12) have
been implicated in neurodegenerative disorders, such as AD.
S100B is a proinflammatory cytokine that triggers glial
cell proliferation in a RAGE-dependent manner [141]. RAGE
is an immunoglobulin-like cell surface receptor that is upreg-
ulated in AD and triggers the expression of proinflammatory
cytokines and mediates A𝛽 transport across the blood-
brain barrier [142–144]. At high micromolar concentrations,
S100B promotes neuroinflammatory processes and neuronal
apoptosis [145]. Increased expression of S100B by plaque-
associated astrocytes in AD contributes to the appearance of
dystrophic neurites overexpressing 𝛽APP in diffuse amyloid
deposits [132]. Astrocytic overexpression of S100B is corre-
lated with the degree of neurite pathology in A𝛽 aggregates
and is induced by interleukin-1 (IL-1), which is secreted by
activated microglia present in the plaques [146]. TNF𝛼, a
cytokine with high levels in AD, decreases S100B expression
in astrocytes but increases its extracellular levels which
can lead to RAGE activation [147]. Furthermore, studies
demonstrated increased susceptibility to neuroinflammation
and neuronal dysfunction after infusion of A𝛽 in trans-
genic mice overexpressing S100B [148]. Interestingly, S100B
interacts with tau in a Zn2+ dependent fashion that could
be responsible for neurite outgrowth [133]. Other studies,
however, suggest that the S100B:tau interaction is mediated
by Ca2+/calmodulin-dependent kinase II and results in the
inhibition of tau phosphorylation [134].
S100A6, S100A9, and S100A12 also have consistently high
levels in samples of AD patients [135, 149]. In particular,
S100A9 is found near neuritic plaques [136, 137] and was
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found to coaggregate with A𝛽 in vitro and form toxic
aggregates [136, 138]. Knockout of S100A9 in a transgenic
mouse resulted in reduced A𝛽 levels in the brain and the
animals presented an improved spatial reference memory
[139]. In agreement with these observations, knockdown of
S100A9 in the AD Tg2576 mice model reduced A𝛽 and
APP C-terminal levels and decreased BACE activity [137].
Induction of S100A9 levels increased intracellular Ca2+ levels,
which in turn upregulated secretion of the inflammatory
cytokines IL-1𝛽 and TNF𝛼 [150]. On the opposite, expression
of exogenous S100A7 in primary corticohippocampal neuron
cultures derived fromTg2576 transgenic embryos inhibits the
generation of A𝛽 and promotes the activity of 𝛼-secretase
[140]. Interestingly, S100 proteins have been found to have
amyloidogenic properties [151–155]. This feature, along with
the high abundance of S100 proteins in protein deposits, their
metal binding properties, dysregulation of Ca2+ signalling,
and the high levels of Cu2+ and Zn2+ in the plaques, will
certainly translate into the elucidation of new functions of
S100 proteins in AD pathomechanisms.
3. Conclusion
Metal homeostasis and balance depend on a number of
biochemical processes and proteins, many of which operate
in the neuronal environment and in the extracellular synaptic
space or at its interface. The biochemistry of this particular
cellular moiety is deeply altered upon aging and under
neurodegeneration, with wide changes in protein levels,
signalling molecules, and metal ion concentrations. Changes
in protein and metal ion homeostasis are hallmark features
across amyloid-forming neurodegenerative diseases and as
we have here overviewed, a number of proteins implicated
in AD are directly regulated by metal-protein interactions; in
some cases, metal ions are even directly involved as modu-
lators of aggregation pathways. Uncovering the mechanistic
details of this cross talk at the biochemical levels in respect
to effects on synaptic protein networks, A𝛽 metabolism and
intra- and extracellular protein aggregation in the context
of concurrent affected processes such as oxidative stress and
neuroinflammation are thus among the major challenges in
modern molecular neurosciences.
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